447 related articles for article (PubMed ID: 18687587)
1. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
Borel P; Benkhoucha M; Weber MS; Zamvil SS; Santiago-Raber ML; Lalive PH
Int Immunol; 2008 Oct; 20(10):1313-9. PubMed ID: 18687587
[TBL] [Abstract][Full Text] [Related]
2. The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW x C57BL/6)F1 male mice, but not in C57BL/6 male mice.
Izui S; Higaki M; Morrow D; Merino R
Eur J Immunol; 1988 Jun; 18(6):911-5. PubMed ID: 3260184
[TBL] [Abstract][Full Text] [Related]
3. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice.
Wofsy D
J Immunol; 1986 Jun; 136(12):4554-60. PubMed ID: 3086436
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
5. IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus.
Shiroiwa W; Tsukamoto K; Ohtsuji M; Lin Q; Ida A; Kodera S; Ohtsuji N; Nakamura K; Tsurui H; Kinoshita K; Nishimura H; Shirai T; Hirose S
Int Immunol; 2007 Feb; 19(2):175-83. PubMed ID: 17189592
[TBL] [Abstract][Full Text] [Related]
6. Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus.
Amano H; Amano E; Santiago-Raber ML; Moll T; Martinez-Soria E; Fossati-Jimack L; Iwamoto M; Rozzo SJ; Kotzin BL; Izui S
Arthritis Rheum; 2005 Sep; 52(9):2790-8. PubMed ID: 16142734
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
8. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
[TBL] [Abstract][Full Text] [Related]
9. Sophorae radix reduces autoimmune response in NZB/w F1 systemic lupus erythematosus mouse model.
Ko E; Lee Y; Park N; Cho C; Yim YN; Kim J; Kim YS; Kim D; Shin MK; Hong MC; Bae H
Lupus; 2007; 16(5):335-41. PubMed ID: 17576735
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice.
Reilly CM; Thomas M; Gogal R; Olgun S; Santo A; Sodhi R; Samy ET; Peng SL; Gilkeson GS; Mishra N
J Autoimmun; 2008 Sep; 31(2):123-30. PubMed ID: 18650065
[TBL] [Abstract][Full Text] [Related]
11. Resistance to tolerance induction is not prerequisite to development of murine SLE.
Izui S; Masuda K
J Immunol; 1984 Dec; 133(6):3010-4. PubMed ID: 6491280
[TBL] [Abstract][Full Text] [Related]
12. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.
Zhang L; Bertucci AM; Smith KA; Xu L; Datta SK
Arthritis Rheum; 2007 Dec; 56(12):4132-41. PubMed ID: 18050205
[TBL] [Abstract][Full Text] [Related]
13. Treatment with high doses of anti-IgM prevents, but with lower doses accelerates autoimmune disease in (NZW x BXSB)F1 hybrid mice.
Cerny A; Starobinski M; Hügin AW; Sutter S; Zinkernagel RM; Izui S
J Immunol; 1987 Jun; 138(12):4222-8. PubMed ID: 3495583
[TBL] [Abstract][Full Text] [Related]
14. Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice.
Santiago-Raber ML; Amano H; Amano E; Baudino L; Otani M; Lin Q; Nimmerjahn F; Verbeek JS; Ravetch JV; Takasaki Y; Hirose S; Izui S
Arthritis Rheum; 2009 Aug; 60(8):2408-17. PubMed ID: 19644866
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
16. Spatial and motor abilities during the course of autoimmune disease in (NZW x BXSB)F1 lupus-prone mice.
Arabo A; Costa O; Tron F; Caston J
Behav Brain Res; 2005 Nov; 165(1):126-37. PubMed ID: 16168499
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of lupus-prone NZM mouse strains to lead exacerbation of systemic lupus erythematosus symptoms.
Hudson CA; Cao L; Kasten-Jolly J; Kirkwood JN; Lawrence DA
J Toxicol Environ Health A; 2003 May; 66(10):895-918. PubMed ID: 12825236
[TBL] [Abstract][Full Text] [Related]
18. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice.
Dong L; Ito S; Ishii KJ; Klinman DM
Arthritis Rheum; 2005 Feb; 52(2):651-8. PubMed ID: 15692999
[TBL] [Abstract][Full Text] [Related]
19. The effect of the phytoestrogen coumestrol on the NZB/W F1 murine model of systemic lupus.
Schoenroth LJ; Hart DA; Pollard KM; Fritzler MJ
J Autoimmun; 2004 Dec; 23(4):323-32. PubMed ID: 15571926
[TBL] [Abstract][Full Text] [Related]
20. [Interleukin 10 in disseminated lupus erythematosus].
Emilie D
J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
